Oslo, November 15, 2024. Navamedic has two loans to Observe Medical ASA, Loan 1
from 27 September 2019, where the current balance, including principal and
accrued interest, is NOK 47,775,182 (as of Oct 31st, 2024) and Loan 2 from 6
September 2023, where the current balance, including principal and accrued
interest, is NOK 6,083,868 (as of Oct 31[st], 2024). Both loans currently have
maturity date of 31.1.2025.

Observe Medical has contacted Navamedic with a request to postpone the maturity
date of the loans.  Navamedic has evaluated and negotiated different
alternatives for the loans Navamedic has granted to Observe Medical.

Navamedic has agreed to the following amendments to the two loan agreements:

Navamedic has agreed to convert NOK 16,354,815.20 of Loan 1 into shares in
Observe Medical ASA at a subscription price of NOK 0.40 per share, provided that
Observe Medical completes its contemplated subsequent offering at a subscription
price of NOK 0,40 with gross proceeds of at least NOK 1.500.000. In total
40,887,038 new shares will be issued to Navamedic upon completion of the
conversion.

Following the conversion, the outstanding balance, including interest, of Loan 1
will be approximately NOK 31,500,000. The due date of Loan 1 will be postponed
from January 31[st], 2025 to December 31[st], 2027, where interest payments will
be made monthly from April 1, 2025 until December 31[st], 2025, following which
an amortization schedule commences, with both principal and interest payments
being paid monthly and the remaining balance will fall due in full on December
31[st], 2027. The interest rate and other terms on Loan 1 will remain unchanged.

Navamedic has further agreed to amend Loan 2 and postpone the due date until
December 31[st], 2027, with interest payments starting on April 1, 2025 and the
remaining balance falling due in full at the due date. The interest rate and
other terms on Loan 2 will remain unchanged.

In the event that Observe Medical's subsequent offering is not completed with a
subscription price of NOK 0.40 with gross proceeds of minimum NOK 1.500.000, the
agreed amendments to the loan agreements including the agreed conversion of
parts of Loan 1, will not be implemented.

For further information, please contact:

Kathrine Gamborg Andreassen, CEO, Navamedic

Mobile: +47 951 78 680

E-mail: kathrine@navamedic.com

Lars Hjarrand, CFO, Navamedic

Mobile: +47 917 62 842

E-mail: lars.hjarrand@navamedic.com

This announcement contains information considered to be inside information
pursuant to the EU Market Abuse Regulation and is subject to the disclosure
requirements pursuant to Section 5-12 the Norwegian Securities Trading Act. The
announcement was published by Lars Hjarrand, CFO of Navamedic ASA, on 15
November 2024 at the time set out above.

About Navamedic

Navamedic ASA is a Nordic pharmaceutical company dedicated to enhancing people's
quality of life by being a reliable supplier of high-quality prescription,
consumer health, and hospital products to hospitals and pharmacies. Our growing
product portfolio has been carefully selected to meet current public health
concerns, such as obesity, Parkinson's disease, and gastro-related ailments, to
empower people to live healthier and more fulfilling lives.

What sets us apart is our deep-rooted commitment to understanding the needs and
requirements of the countries where we are present. Our local insight and
competence enable us to understand the specific needs of each country where we
operate and ultimately to gain market access. This makes us a preferred partner
for international companies expanding their footprint across the Nordics and
Benelux regions, through either in-licensing or out-licensing. Navamedic has
been listed on the Oslo Stock Exchange since 2006 (ticker: NAVA) and is
headquartered in Oslo, Norway.

For more information, please visit Navamedic.com.